Exclusive Summary

• Listed as a WHO Essential Medicine, holding an irreplaceable first-line guideline-recommended status for specific conditions such as migraine prophylaxis, essential tremor, and portal hypertension.
• The originator patent has long expired, and its broad indications cover billions of patients globally with hypertension, cardiovascular, and neurological diseases, ensuring massive and highly stable market demand.
• Leveraging China's robust vertical integration (API-to-Finished Product) and supply chain advantages, it offers immense production elasticity and significant cost-effectiveness, ideal for global public procurement tenders and commercial pharmacy distribution.
• Providing a flexible 'Distribution' partnership model backed by ready-to-file, highly compliant CTD dossiers, enabling rapid response to support overseas clients in completing local registration and market access.